Letai A - Search Results

1

Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.

Sarosiek KA, Letai A. Sarosiek KA, et al. Among authors: letai a. FEBS J. 2016 Oct;283(19):3523-3533. doi: 10.1111/febs.13714. FEBS J. 2016. PMID: 26996748 Free PMC article. Review.

2

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Letai A, et al. Cancer Cell. 2002 Sep;2(3):183-92. doi: 10.1016/s1535-6108(02)00127-7. Cancer Cell. 2002. PMID: 12242151 Free article.

3

BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics.

Letai A. Letai A. Expert Opin Biol Ther. 2003 Apr;3(2):293-304. doi: 10.1517/14712598.3.2.293. Expert Opin Biol Ther. 2003. PMID: 12662143

4

Pharmacological manipulation of Bcl-2 family members to control cell death.

Letai A. Letai A. J Clin Invest. 2005 Oct;115(10):2648-55. doi: 10.1172/JCI26250. J Clin Invest. 2005. PMID: 16200198 Free PMC article.

5

Restoring cancer's death sentence.

Letai A. Letai A. Cancer Cell. 2006 Nov;10(5):343-5. doi: 10.1016/j.ccr.2006.10.014. Cancer Cell. 2006. PMID: 17097553 Free article.

6

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. Deng J, et al. Among authors: letai a. Cancer Cell. 2007 Aug;12(2):171-85. doi: 10.1016/j.ccr.2007.07.001. Cancer Cell. 2007. PMID: 17692808 Free article.

7

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. Del Gaizo Moore V, et al. Among authors: letai a. Blood. 2008 Feb 15;111(4):2300-9. doi: 10.1182/blood-2007-06-098012. Epub 2007 Dec 4. Blood. 2008. PMID: 18056841 Free PMC article.

8

Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.

Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A. Deng J, et al. Among authors: letai a. Cancer Res. 2007 Dec 15;67(24):11867-75. doi: 10.1158/0008-5472.CAN-07-1961. Cancer Res. 2007. PMID: 18089817

9

Diagnosing and exploiting cancer's addiction to blocks in apoptosis.

Letai AG. Letai AG. Nat Rev Cancer. 2008 Feb;8(2):121-32. doi: 10.1038/nrc2297. Nat Rev Cancer. 2008. PMID: 18202696 Review.

10

Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?

Del Gaizo Moore V, Letai A. Del Gaizo Moore V, et al. Among authors: letai a. Adv Exp Med Biol. 2008;615:159-75. doi: 10.1007/978-1-4020-6554-5_8. Adv Exp Med Biol. 2008. PMID: 18437895 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters